Silence Therapeutics
SLN
69 hedge funds and large institutions have $493M invested in Silence Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 15 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
0.69% more ownership
Funds ownership: 19.45% → 20.14% (+0.69%)
2% less capital invested
Capital invested by funds: $502M → $493M (-$8.96M)
3% less funds holding
Funds holding: 71 → 69 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
78% less call options, than puts
Call options by funds: $8K | Put options by funds: $36K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$11.9M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$8.95M |
| 3 |
Morgan Stanley
New York
|
+$7.77M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$6.3M |
| 5 |
Millennium Management
New York
|
+$6.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$52.8M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$23.7M |
| 3 |
FTM
First Turn Management
Del Mar,
California
|
-$10.2M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.69M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.21M |
SLN Hedge Fund Activity: Q3 2024 in Review
69 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2024, worth a combined $493M — down 1.8% from $502M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SLN and 13 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 24 added.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $11.9M. The largest seller was Artal Group, exiting entirely with an estimated $52.8M sold.
- 69 institutional investors held Silence Therapeutics (SLN) as of Q3 2024, down from 71 in Q2 2024.
- Funds reported $493M of Silence Therapeutics stock for Q3 2024, down 1.8% quarter-over-quarter.
- 13 funds opened new Silence Therapeutics positions in Q3 2024 and 15 closed out, a net change of -2 holders.
- The largest Silence Therapeutics buyer in Q3 2024 was Eventide Asset Management, an estimated $11.9M added.
- The largest Silence Therapeutics seller in Q3 2024 was Artal Group, an estimated $52.8M sold.
Based on aggregated 13F filings for Q3 2024.